Purpose To present a case of branch retinal vein occlusion (BRVO) following ChAdOx1 nCoV-19 (Oxford-AstraZeneca) Vaccine. Methods Case report. Results A 60-year old otherwise healthy Caucasian male, presented to the ophthalmology emergency clinic complaining of sudden, painless vision loss in his right eye of 24 h” duration. The patient had received Vaxveria seven days prior. The clinical and fundus examination of the right eye established the diagnosis of BRVO. Conclusion The present case descibes the occurrence of BRVO soon after the vaccination with the Oxford-AstraZeneca vaccine. The close temporal relationship between the BRVO incidence and the vaccination is reinforced by the lack of othe subjective cause to justify the episode.

Précis: Ahmed Valve and Baerveldt shunt are efficacious options in vitrectomized eyes. Baerveldt implant achieves a lower mean intraocular pressure (IOP) at 2 years, with fewer medications and a higher percentage of medication-free patients.Purpose: To investigate and compare the efficacy and complications between Ahmed FP7 Glaucoma Valve (AGV) and Baerveldt 101-350 Glaucoma Implant (BGI) in vitrectomized eyes. Materials and Methods:In this single-center randomized clinical trial, 43 vitrectomized eyes (39 patients) underwent glaucoma drainage device implantation. Eyes were randomized to receive either an AGV (FP7) or a BGI (101-350) and were followed for 2 years. Surgical success was defined as an IOP measurement ≤ 18 mm Hg and ≥ 5 mm Hg with or without glaucoma medication at 2 or more sequential visits after 3 months. The primary outcome was the comparison of the success rate at 2 years, while mean IOP, mean number of medications, and number of complications were considered secondary outcomes.Results: Kaplan-Meier estimates of the 2-year success rates in IOP control after GDD implantation were similar between the 2 groups; AGV group 81.8% (95% CI: 67.2%-99.6%) and BGI group 85.7% (95% CI: 72.0%-100.0%), (log-rank test P value = 0.74). Patients in the BGI group had a statistically significant lower mean IOP compared with the AGV group in all follow-up visits at 2, 6, 12, and 24 months (11.62 vs. 17.45 mm Hg at the latter P value <0.001). The BGI group required a significantly lower number of medications for IOP control at the 2-year visit compared with the AGV group (0.76 ± 0.99 vs. 1.5 ± 1.06 P value = 0.02) but had a higher number of complications (62% vs. 41%, respectively).Conclusions: GDDs provide a viable solution for IOP control in vitrectomized eyes. Based on our prospective comparison, both Ahmed FP7 Glaucoma Valve and Baerveldt 101-350 Glaucoma Implant are efficacious options.

BackgroundTo assess the visual and refractive outcomes of the non-diffractive extended depth of focus (EDOF) AcrySof ® IQ Vivity™ (Alcon, Fort Worth, TX, USA) intraocular lens (IOL) after bilateral implantation in patients undergoing phacoemulsification surgery. MethodsIn this prospective non-comparative study, 20 patients willing to undergo bilateral implantation of AcrySof ® IQ Vivity™ IOL were recruited at a single center (Eye Day Clinic, Athens, Greece). Pre- and post-operative clinical assessment of the patients included slit lamp examination, assessment of corrected distance visual acuity (CDVA) at 6 m, uncorrected distance visual acuity (UDVA) at 6 m, uncorrected intermediate visual acuity (UIVA) at 66 cm, uncorrected near visual acuity (UNVA) at 33 cm and optical biometry. Moreover, the presence of visual disturbances and the contrast sensitivity (CS) thresholds of all patients were assessed.ResultsThe mean ± standard deviation (SD) of monocular UDVA, UIVA and UNVA were 0.05 ± 0.08, 0.07 ± 0.09 and 0.23 ± 0.09 LogMAR, respectively. More specifically, 97.5%, 70% and 15% of eyes achieved UDVA, UIVA and UNVA of 20/25 or higher, while 6 patients in total reported mild glare, blurred vision, fluctuation in vision and/or depth perception difficulty. The mean ± SD of LogCS threshold was 1.68 ± 0.26.ConclusionsBilateral implantation of AcrySof ® IQ Vivity™ IOL could be a solution to patients seeking independence from optical aids. Further comparative studies are warranted to confirm our results.

No abstract